Pharmacological treatment of central nervous system trauma

Pharmacology and Toxicology

Volumn 78, Issue 1, 1996, Pages 12-17

  Faden, A I ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

21 AMINOSTEROID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ATROPINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DEFEROXAMINE; EMOPAMIL; GANGLIOSIDE; GANGLIOSIDE GM1; GLUTAMATE RECEPTOR ANTAGONIST; METHYLPREDNISOLONE; MIANSERIN; NALOXONE; NEUROPROTECTIVE AGENT; OPIATE ANTAGONIST; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTIRELIN; PROTIRELIN DERIVATIVE; SCAVENGER; SEROTONIN ANTAGONIST; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE SYNTHASE INHIBITOR; TIRILAZAD; UNINDEXED DRUG;

ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; BRAIN INJURY; BRAIN PROTECTION; CLINICAL TRIAL; DRUG DEVELOPMENT; DRUG MECHANISM; HUMAN; MONOAMINE METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPINAL CORD LESION; TISSUE INJURY;

EID: 0030061481     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1996.tb00173.x     Document Type: Review

References (63)

1. Anderson, D. K., T. R. Waters & E. D. Means: Pretreatment with alpha‐tocopherol enhances neurologic recovery after experimental spinal cord compression injury. J. Neurotrauma 1988, 5, 61–68.
2. Baron, K. D., M. P. Dentinger, H. K. Kimelberg, L. R. Nelson, R. S. Bourke, S. Keegan, et al.: Ultrastructural features of a brain injury model in the cat. I. Vascular and neurological changes and the prevention fo astroglial swelling by L‐644,711. Ada neuropathol. 1994, 39, 340–350.
3. Behrmann, D. L., J. C. Bresnahan & M. S. Beattie: Modelling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone U74006F and YM‐14673. Exp. Neural. 1994, 126, 61–75.
4. Boloventa, P., F. Wandosell & M. Nieto‐Sampedro: CNS glial scar tissue: a source of molecules which inhibit central neuric outgrowth. In: Neuronal‐astrocytic interactions: Pathological implications. Eds.: Yu, A. C. H., L. Hertz, M. D. Norenberg, E. Sykova & S. G. Waxman. Elsevier Amsterdam 1992, pp. 367–380.
5. Bracken, M. B. & T. R. Holford: Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long tract neurological function in NASCIS 2. J. Neurosurg. 1993, 79, 500–507.
6. Bracken, M. B., M. J. Shepard, W. F. Collins, T. R. Holford, W. Young, D. S. Baskin, et al.: A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the second National Acute Spinal Cord Injury Study. New Engl. J. Med. 1990, 322, 1405–1411.
7. Braughler, J. M., R. L. Chase & G. L. Neft: A new 21‐aminosteroid antioxidant lacking glucocorticoid activity blocks arachidonic acid release and stimulates ACTH secretion from mouse pituitary tumor (A+T‐20) cells. J. Pharmacol. Exp. Therap. 1988, 244, 423–427.
8. Ceylan, S., A. Kalelioglu, G. Aktürk & S. Ceylan: Medical treatment of acute spinal cord injuries. Res. Exp. Med. 1990, 190, 111–119.
9. Choi, D. W.: Ion dependence of glutamate neurotoxicity. J. Neurosci. 1987, 7, 369–379.
10. Constantini, S. & W. Young: The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J. Neurosurg. 1994, 78, 97–111.
11. Doucet, J. P., S. P. Squinto & J. N. G. Bazan: Fos‐jun and the primary genomic response in the nervous system. Mol. Neurobiol. 1990, xx, 27–55.
12. Dragunow, M., M. Goulding, R. L. M. Faull, R. Ralph & Mee E. & R. Friths: Induction of c‐fos raRNA and proteins in neurons and glia after traumatic brain injury: pharmacological characterization. Exp. Neurol. 1990, 107, 236–248.
13. Faden, A. I.: Comparison of single vs. combination drug strategies in experimental brain trauma. J. Neurotrauma 1993a, 10, 91–100.
14. Faden, A. I.: Role of opioids in central nervous system injury. In: Handbook of experimental pharmacology. Eds.: A. Herz, H. Akil & E. J. Simon. Springer‐Verlag, Berlin 1993b, pp. 325–341.
15. Faden, A. I. & P. S. Halt: Platelet‐activating factor reduces spinal cord blood flow and causes behavioral deficits after intrathecal administration in rats through a specific receptor mechanism. J. Pharmacol. Exp. Therap. 1992, 261, 1064–1070.
16. Faden, A. I. & S. K. Salzman: Experimental pharmacology. In: The neurobiology of CNS trauma. Eds.: S. K. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 227–244.
17. Faden, A. I. & P. Tzendzalian: Platelet activating factor antagonists limit glycine changes and behavioral deficits after brain trauma. Amer. J. Physiol. 1992, 263, R909–R914.
18. Ford, W. J. & D. N. Malm: Failure of nimodipine to reverse acute experimental spinal cord injury. CNS Trauma 1985, 2, 9–17.
19. Geisler, F. H., F. C. Dorsey & W. P. Coleman: Recovery of motor function after spinal cord injury ‐ a randomized, placebo‐controlled trial with ganglioside. New Engl. J. Med. 1991, 324, 1829–1838.
20. Giulian, D.: The consequences of inflammation after injury to the central nervous system. In: The neurobiology of CNS trauma. Eds.: S. K. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 155–164.
21. Gorio, A., G. Ferrari, M. Fusco, D. Janigro, R. Zanoni & G. Jonsson: Gangliosides and their effects on rearranging peripheral and central neural pathways. Cent. Nerv. Syst. Trauma 1984, 1, 29–37.
22. Graham, S. H., J. Chen, J. Lan, J. Leach & R. P. Simon: Neuroprotective effects of a use‐dependent blocker of voltage‐dependent sodium channel, BW619C89, in rat middle cerebral artery occlusion. J. Pharmacol. Exp. Therap. 1994, 269, 854–859.
23. Graham, S. H., J. Chen, F. R. Sharp & R. P. Simon: Limiting ischemic injury by inhibition of excitatory amino acid release. J. Cereb. Blood Flow Metab. 1993, 13, 88–97.
24. Hagg, R., J.‐C. Louis, F. Longo & S. Varon: Neurotrophic factors, growth factors and CNS trauma. In: The neurobiology of CNS trauma. Eds.: S. K. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 245–265.
25. Hall, E. D.: The neuroprotective pharmacology of methylprednisolone. J. Neurosurg 1992, 76, 13–22.
26. Hall, E. D. & J. M. Braughler: Role of lipid peroxidation in post‐traumatic spinal cord degeneration: a review. CNS Trauma 1988, 3, 281–294.
27. Hall, E. D. & J. M. Braughler: Free radicals in CNS injury. In: Molecular and cellular approaches in the treatment of neurological disease. Ed.: S. G. Waxman Raven Press, New York 1993, pp. 81–105.
28. Hall, E. D. & D. L. Wolf: A pharmacological analysis of the pathophysiological mechanisms of posttraumatic spinal cord ischemia. J. Neurosurg. 1986, 64, 951–961.
29. Hall, E. D., D. L. Wolf, J. S. Althaus & P. F. Von Voigtlander: Beneficial effects of the K‐opioid receptor agonist U‐50488H in experimental acute brain and spinal cord injury. Brain Res. 1987, 435, 174–180.
30. Hallenbeck, J. M., T. P. Jacobs & A. I. Faden: Combined PGI 2, indomethacin and heparin improves neurological recovery after spinal trauma in cats. J. Neurosurg. 1983, 58, 749–754.
31. Hsu, C. Y., T.‐N. Lin, J. Xu, J. Chao & E. L. Hogan: Kinins and related inflammatory mediators in central nervous system injury. In: The neurobiology of CNS trauma. Eds.: S. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 145–154.
32. Ikeda, Y., K. Ikeda & D. M. Long: Protective effect of the iron chelator deferoxamine on cold‐induced brain edema. J. Neurosurg. 1989, 71, 233–238.
33. Kimelberg, H. K. & M. D. Norenberg: Astrocytic responses to CNS trauma. In: The neurobiology of CNS trauma. Eds.: S. K. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 193–208.
34. Lyeth, B. G., C. E. Dixon, R. J. Hamm, L. W. Jenkins, H. F. Young, H. H. Stonnington & R. L. Hayes: Effects of anticholinergic treatment on transient behavioral suppression and physiologic responses following concussive brain injury to the rat. Brain Res. 1988, 448, 88–97.
35. Magel, E., J.‐C. Louis, J. Aguilera & E. Yavin: Gangliosides prevent ischemia‐induced down regulation of protein kinase C in fetal rat brain. J. Neurochem. 1990, 55, 2126–2131.
36. Mattson, M. P. & S. W. Scheff: Endogenous neuroprotection factors and traumatic brain injury: mechanism of action and implications for therapy. J. Neurotrauma 1994, 11, 3–34.
37. McIntosh, T. K.: Neurochemical sequelae of traumatic brain injury: therapeutic implications. Cereb. Brain Metab. Rev. 1994, 6, 109–162.
38. Mclntosh, T. K. & A. I. Faden: Endogenous opioid peptides and traumatic central nervous system injury. In: The neurobiology of CNS trauma. Eds.: S. K. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 165–172.
39. Muizelaar, J. P., A. Marmarou, H. F. Young, S. C. Choi, A. Wolf, R. L. Schneider, et al.: Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol‐conjugated superoxide dismutase: a Phase II trial. J. Neurosurg. 1993, 78, 375–382.
40. Nicoletti, F, S. Cavallaro, V. Bruno, M. Virgili, M. V. Catania, A. Contestabile & P. L. Canonico: Gangliosides attenuate NMDA receptor‐mediated excitatory amino acid release in cultured cerebellar neurons. Neuropharmacology 1989, 28, 1283–1286.
41. Ohnishi, S. T., J. K. Barr, C. Katagi & M. Katsuska: Protection of rat spinal cord against contusion injury by new prostaglandin derivatives. Arnzneimittelforsch./Drug Res. 1989, 39, 236–239.
42. Okiyama, K., D. H. Smith, T. A. Gennarelli, R. P. Simon, M. Leach & T. K. McIntosh: The sodium channel blocker and glutamate release inhibitor BW1003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J. Neurochem. 1995, 64, 802–809.
43. Panter, S. S. & A. I. Faden: Biochemical changes and secondary injury from stroke and trauma. In: Principles and practice of restorative neurology. Eds.: R. R. Young & P. J. Delwade. Butter‐worths, New York 1992, pp. 32–52.
44. Pitts, L. H., A. Ross, G. A. Chase & A. I. Faden: Treatment with thyrotropin‐releasing hormone (TRH) in patients with traumatic spinal cord injuries. J. Neurotrauma 1995, 12, 235–243.
45. Puniak, M. A., G. M. Freeman, C. A. Agresta, L. Van Newkirk, C. A. Barone & S. K. Salzman: Comparison of serotonin antagonist, opioid antagonist and TRH analog for the acute treatment of experimental spinal trauma. J. Neurotrauma 1991, 8, 193–203.
46. Regan, R. F. & D. W. Choi: Excitotoxicity and central nervous system trauma. In: The neurobiology of CNS trauma. Eds.: S. K. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 173–181.
47. Relton, J. K. & N. J. Rothwell: Interleukin‐I receptor antagonist inhibits ischaemic and excitotixic neuronal damage in the rat. Brain Res. Bull. 1992, 29, 243–246.
48. Rothwell, M. J. & S. J. Hopkins: Cytokines and the nervous system II: actions and mechanisms of action. Trends Neurosci. 1995, 18, 130–136.
49. Sabel, B. A., M. D. Slavin & D. G. Stein: GM 1 ganglioside treatment facilitates behavioral recovery from brain damage. Science 1984, 225, 340–342.
50. Salzman, S. K., G. Kelly, J. Chavin, L. Wang, M. A. Puniak, C. A. Agresta, & S. Azim: Characterization of mianserin neuroprotection in experimental spinal trauma: dose/route response and late treatment. J. Pharmacol. Exp. Therap. 1994, 269, 322–328.
51. Siesjo, B. K.: Historical overview: calcium, ischemia, and death of brain cells. Ann N. Y. Accd. Sci. 1988, 522, 638–661.
52. Sun, F.‐Y. & A. I. Faden: Neuroprotective effects of 619C89, a use‐dependent sodium channel blocker, in rat. Brain Res. 1995, 673, 133–140.
53. Sun, F.‐Y. & A. I. Faden: Pretreatment with antisense oligodeoxyn‐ucleotides directed against the NMDA‐R1 receptor enhances survival and behavioral recovery following traumatic brain injury in rats. Brain Res. 1995, 693, 163–168.
54. Taupin, V, S. Toulmond, A. Serrano. J. Benavides & F. Zavala: Increase in IL‐6, IL‐1 and TNF levels in rat brain following traumatic lesion. J. Neuroimmunol. 1993, 42, 177–186.
55. Teasdale, G.: A randomized trial of nimodipine in severe head injury: HIT 1. J. Neurotrauma 1991, 37, S545–S550.
56. Toulmond, S. E., McGowan & N. J. Rothwell: Neuroprotective effects of IL‐1 receptor antagonist (IL‐1ra) after brain trauma in the rat. Soc. Neurosci. Abstr. 1994, 20, 193.
57. Vink, R.: The measurement of metabolic changes after central nervous system trauma. In: The neurobiologg of CNS trauma. Eds.: S. K. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 68–78.
58. Vink, R., P. S. Portoghese & A. I. Faden: Kappa‐opioid antagonist improves cellular bioenergetics and recovery after traumatic brain injury. Amer. J. Physiol. 1991, 261, R1527–R1532.
59. Ward, A. Jr.: Atropine and the treatment of closed head injury. J. Neurosurg. 1950, 7, 38–401.
60. Wei, E. P., H. A. Kontos, W D. Dietrich, J. T. Povlishock & E. F. Ellis: Inhibition by free radical scavengers of cyclooxygenase inhibitors of pial arteriolar abnormalities from concussive brain injury in cats. Circ. Res. 1981, 48, 95–103.
61. Wrathall, J. R., Y. D. Teng, D. Choiniere & D. J. Mundt: Evidence that local non‐NMDA receptors contribute to functional deficits in contusive spinal cord injury. Brain Rex. 1992, 586, 140–143.
62. Young, W & S. Constantini: Ionic and water shifts in injured central nervous tissues. In: The neurobiology of CNS trauma. Eds.: S. K. Salzman & A. I. Faden. Oxford University Press, New York 1994, pp. 123–138.
63. Yue, T.‐L. & G. Feuerstein: Platelet‐activating factor: a putative neuromodulator and mediator in the pathophysiology of brain injury. Crit. Rev. Neurobiol. 1994, 8, 11–24.